Emerging biological therapies to treat acute lymphoblastic leukemia

References

• Biological therapies for cancer. [cited 2016 Oct 25]. Available from: https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet
   Google Scholar
• Targeted cancer therapies. [cited 2016 Oct 25]. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/fact-sheet
   Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision of the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Pui C-H, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood. 2012;120(6):1165–1174.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532–543.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012 Oct 1;122(10):3407–3415.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Gianfelici V, O’Brien SM, et al. Advances in the genetics and therapy of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2016;35:e314–e322.
   PubMedGoogle Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–3749.
   PubMed Web of Science ®Google Scholar
• Egler RA, Ahuja SP, Matloub Y. L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. J Pharmacol Pharmacother. 2016;7:62–7110.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Drugs approved for leukemia. [cited 2016 Oct 25]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/leukemia
   Google Scholar
• Jones L, Carol H, Evans K, et al. A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the pediatric preclinical testing program. Leuk Advance. [Online publication 2016 Aug 12]. DOI:10.1038/leu.2016.192
   Google Scholar
• Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124:3738–3747.
   PubMed Web of Science ®Google Scholar
• Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128:1382–1395.
   PubMed Web of Science ®Google Scholar
• Leonard JT, Rowley JS, Eide CA, et al. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Sci Transl Med. 2016;8(354):354ra114.
   PubMed Web of Science ®Google Scholar
• Dhédin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015;125:2486–2496.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Sanz G, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute. Leukemia. 2015;29(9):1891–1900.
   PubMed Web of Science ®Google Scholar
• Graça M. Dores, Susan S. Devesa, Curtis Re, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119:34–43.
   PubMed Web of Science ®Google Scholar
• Rae C, Furlong W, Jankovic M, et al. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood. Eur J Cancer Care (Engl). 2014;23(6):779–785.
   PubMed Web of Science ®Google Scholar
• Kaul S, Korgenski EK, Ying J, et al. A retrospective analysis of treatment-related hospitalization costs of pediatric, adolescent, and young adult acute lymphoblastic leukemia. Cancer Med. 2016;5:221–229.
   PubMed Web of Science ®Google Scholar
• Van Litsenburg RR, Uyl-de Groot CA, Raat H, et al. Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology. Pediatr Blood Cancer. 2011;57:1005–1010.
   PubMed Web of Science ®Google Scholar
• Dombret H, Thomas X, Chevallier P, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. J Med Econ. 2016;19:1034–1039.
   PubMed Web of Science ®Google Scholar
• Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783–1786.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Ravandi F, et al. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015;125:4010–4016.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–3889.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Huettmann A, Kaul F, et al. Immunochemotherapy with rituximab improves molecular CR rate and outcome in CD20+ B-lineage standard and high risk patients; results of 263 CD20+ patients studied prospectively in GMALL study 07/2003. Blood. 2011;116:77–78.
   Web of Science ®Google Scholar
• Maury S, Chevret S, Thomas X, et al. Addition of rituximab improves the outcome of adult patients with CD20-positive, Ph-negative, B-cell precursor acute lymphoblastic leukemia (BCP-ALL): results of the randomized GRAALL-R 2005 study. Blood. 2015;126:1.
   PubMed Web of Science ®Google Scholar
• Stolz C, Hess G, Hähnel PS, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood. 2008;112:3312–3321.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;151:47–53.
   PubMed Web of Science ®Google Scholar
• Rahmé R, Benayoun E, Pautas C, et al. Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report. Exp Hematol. 2013;41(6):505–507.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Thomas D, et al. Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive acute lymphoblastic leukemia (ALL). Blood. 2013;122:2664.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Ayello J, Van De Ven C, et al. Comparative study of obinutuzumab (GA101) vs. rituximab against CD20+ rituximab-sensitive and -resistant burkitt (BL) and acute lymphoblastic leukemia (B-ALL): potential targeted therapy in patients with high risk BL and pre-B-ALL. Blood. 2014;124:2251.
   Web of Science ®Google Scholar
• Kantarjian HM, Lioure B, Kim SK, et al. A phase II study of coltuximab ravtansine (SAR3419) monotherapy in patients with relapsed or refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2016;1:139–145.
   Web of Science ®Google Scholar
• Fathi AT, Borate U, DeAngelo DJ, et al. A phase 1 study of denintuzumab mafodotin (SGN-CD19A) in adults with relapsed or refractory B-lineage acute leukemia (B-ALL) and highly aggressive lymphoma. Blood. 2015;126:1328.
   Web of Science ®Google Scholar
• Anja Löffler A, Peter Kufer P, Ralf Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098–2103.
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012 Jun 28;119(26):6226–6233.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134–4140.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578–2584.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Kantarjian H, Brüggemann M, et al. An evaluation of molecular response in a phase 2 open-label, multicenter confirmatory study in patients (pts) with relapsed/refractory b-precursor acute lymphoblastic leukemia (R/R ALL) receiving treatment with the BiTE® antibody construct blinatumomab. Blood. 2014;124:3704.
   Web of Science ®Google Scholar
• Martinelli G, Dombret H, Chevallier P, et al. Complete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA). Blood. 2015;126:679.
   Web of Science ®Google Scholar
• Topp MS, Stein A, Gökbuget N. Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Haematologica. 2016;101(s1):22.
   Google Scholar
• Topp MS, Kufer P, Gökbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Goekbuget N, Viardot A, et al. Long-term survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) who achieved minimal residual disease (MRD) response following anti-CD19 BiTE® blinatumomab. Blood. 2014;124:2287.
   Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126:680.
   Web of Science ®Google Scholar
• Stein A, Topp MS, Goekbuget N, et al. Allogeneic hematopoietic stem cell transplantation following anti-CD19 BiTE® blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). Blood. 2014;124:965.
   Google Scholar
• Topp MS, Gökbuget N, O’Brien S, et al. Influence of baseline factors on outcomes in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL) treated with blinatumomab. Haematologica. 2015;100(s1):30.
   Google Scholar
• Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126:2578–2584.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–5157.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4:244.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Stein AS, Bargou RC, et al. Safety and activity of blinatumomab for older patients (pts) with relapsed/refractory (R/R) B-precursor acute lymphoblastic leukemia (ALL) in two phase 2 studies. J Clin Oncol. 2015;33:7043.
   Web of Science ®Google Scholar
• Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from two phase 2 studies. Cancer. 2016;122:2178–2185.
   PubMed Web of Science ®Google Scholar
• Thomas X. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol. 2015;16:6–7.
   PubMed Web of Science ®Google Scholar
• Topp MS, Stelljes M, Zugmaier G, et al. Retreatment with blinatumomab after CD19-positive relapse: experience from 3 trials in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). Haematologica. 2015;100(s1):31–32.
   Google Scholar
• Sokolov A, Parovichnikova E, Troitskay V, et al. Combined blinatumomab + dasatinib/ibrutinib therapy of relapsed acute lymphoblastic leukemia patients. Antileukemic effect on the T-helper and T-regulatory cells reduction background. Haematologica. 2016;101(s1):354.
   Google Scholar
• Przepiorka D, Ko C-W, Deisseroth A, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21:4035–4039.
   PubMed Web of Science ®Google Scholar
• Sanford M. Blinatumomab: first global approval. Drugs. 2015;75:321–327.
   PubMed Web of Science ®Google Scholar
• Schlegel P, Lang P, Zugmaier G, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica. 2014;99:1212.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Handgretinger R, Locatelli F, et al. A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2013;122:70.
   Web of Science ®Google Scholar
• Gore L, Locatelli F, Zugmaier G, et al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2014;124:3703.
   Web of Science ®Google Scholar
• Meany HJ, Seibel NL, Krailo MJ, et al. Feasability study of a novel experimental induction protocol combining B43-PAP (anti-CD19) immunotoxin with standard induction chemotherapy in children and adolescents with relapsed B-lineage ALL: a report from the Children’s Oncology Group. Immunother. 2015;38:299–305.
   Web of Science ®Google Scholar
• Raetz EA, Cairo MS, Borowitz MJ, et al. Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase ii results from Children’s Oncology Group (COG) study ADVL04P2.Pediatr. Pediatr Blood Cancer. 2015;62:1171–1175.
   PubMed Web of Science ®Google Scholar
• Advani AS, McDonough S, Coutre S, et al. SWOG S0910: A phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014;165:504–509.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Huguet F, Raffoux E, et al. Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica. 2015;100:e128–e131.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Eugene T, Robillard N, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2:e108–e117.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Bodet-Milin C, Robillard N, et al. BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Eur J Haematol. 2013;91:552–556.
   PubMed Web of Science ®Google Scholar
• De Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia. 2012;26:255–264.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stock W, Shustov AR, et al. Weekly inotuzumab ozogamicin (Ino) in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL). Blood. 2013;122:3906.
   Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403–411.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–2736.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, O’Brien S, et al. 3721 salvage chemotherapy with inotuzumab ozogamicin (INO) combined with mini-hyper-CVD for adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). Blood. 2015;126:3721.
   Web of Science ®Google Scholar
• Elias Jabbour E, Susan O’Brien S, Koji Sasaki K, et al. Frontline inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) for older patients with acute lymphoblastic leukemia (ALL). Blood. 2015;126:83.
   Web of Science ®Google Scholar
• Jabbour EJ, Advani AS, Stelljes M, et al. Efficacy and safety of inotuzumab ozogamicin in older patients with relapsed/refractory acute lymphoblastic leukemia enrolled in the global phase 3 randomized controlled INO-VATE trial. Haematologica. 2016;101(s1):32.
   Google Scholar
• DeAngelo DJ, Jabbour EJ, Stelljes M, et al. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the global phase 3 randomized controlled INO-VATE trial: efficacy and safety by prior therapy. Haematologica. 2016;101(s1):184.
   Google Scholar
• Kantarjian HM, DeAngelo DJ, Advani AS, et al. Overall survival in relapsed/refractory B-cell acute lymphoblastic leukemia patients receiving inotuzumab ozogamicin vs standard care in the phase 3 INO-VATE study. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Haematologica. 2016;101(s1):339.
   Google Scholar
• Kantarjian HM, Su Y, Bhattacharyya H, et al. Patient-reported outcomes from a global phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard care for relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(s1):202.
   Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016. [Published online 12 Jun 2016]. DOI:10.1056/NEJMoa1509277
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Wilhelm K, Ravandi F, et al. Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013;13:296–301.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010;16:1894–1903.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Bhojwani D, Silverman LB, et al. A novel anti-CD22 immunotoxin, moxetumomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL). Blood. 2011;118:248.
   Web of Science ®Google Scholar
• Ravandi F, Cortes J, Thomas D, et al. Phase I Istudy of moxetumomab pasudotox in adult patients with relapsed or refractory acute lymphoblastic leukemia. Haematologica. 2016;101(s1):351.
   Google Scholar
• Herrera L, Bostrom B, Gore L, et al. A phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2009;31:936–941.
   PubMed Web of Science ®Google Scholar
• Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2011;154:471–476.
   PubMed Web of Science ®Google Scholar
• Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645–2651.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Isnard F, Garderet L, et al. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol. 2013;91:315–321.
   PubMed Web of Science ®Google Scholar
• Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B study (CALGB 10102). Blood. 2009;114:838.
   Web of Science ®Google Scholar
• Papayannidis C, Derenzini E, Iacobucci I, et al. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. Am J Hematol. 2009;84:849–850.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Mahe B, Garand R. Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. Int J Hematol. 2008;88:209–211.
   PubMed Web of Science ®Google Scholar
• Balduzzi A, Rossi V, Corral L, et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia. 2003;17:2247–2248.
   PubMed Web of Science ®Google Scholar
• Strickland SA, Glenn M, Zheng W, et al. SAR650984, a CD38 monoclonal antibody in patients with selected CD38+ hematological malignancies – data from a dose-escalation phase I study. Blood. 2013; 122:284.
   Web of Science ®Google Scholar
• Chevallier P, Robillard N, Wuilleme-Toumi S, et al. Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukaemia patients and is associated with chemoresistance in these patients. Haematologica. 2004;89(11):1399–1401.
   PubMed Web of Science ®Google Scholar
• Chevallier P, Robillard N, Charbonnier A, et al. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood. 2012;119(11):2474–2477.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. CAR-T cell therapy: engineering patients’immune cells to treat their cancers. [cited 2016 Jun 20] Available from: http://www.cancer.gov/about-cancer/treatment/research/car-t-cells
   Google Scholar
• Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. ASH Education Book. 2014;2014:559–564.
   Google Scholar
• Lee D, Kochenderfer J, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–1518.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Maude SL, Shaw PA, et al. Durable remissions in children with relapsed/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019). Grupp SA, Maude SL, Shaw PA, et al. Blood. 2015;126:681.
   Web of Science ®Google Scholar
• Maude S, Teachey D, Rheingold S, et al. Durable remissions after monotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory ALL. Haematologica. 2016;01(s1):183–184.
   Google Scholar
• Turtle C, Sommermeyer D, Berger C, et al. Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition. Blood. 2014;124:384.
   Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. J Clin Oncol. 2016;34:102.
   Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
   PubMed Web of Science ®Google Scholar
• Park JH, Riviere I, Wang X, et al. Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19-targeted 19-28z CAR modified t cells in adult patients with relapsed, refractory B-cell ALL. Blood. 2015;126:682.
   Web of Science ®Google Scholar
• Kebriaei P, Huls H, Singh H, et al. Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor. Blood. 2014;124:311.
   Web of Science ®Google Scholar
• Kebriaei P, Ciurea SO, Huls MH, et al. Pre-emptive donor lymphocyte infusion with CD19-directed, CAR-modified T cells infused after allogeneic hematopoietic cell transplantation for patients with advanced CD19+ malignancies. Blood. 2015;126:862.
   Google Scholar
• Maude SL, Barrett DM, Rheingold SR, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. J Clin Oncol. 2016;34:3007.
   Google Scholar
• Lee DW, Stetler-Stevenson M, Yuan CM, et al. Safety and response of incorporating CD19 chimeric antigen receptor T cell therapy in typical salvage regimens for children and young adults with acute lymphoblastic leukemia. Blood. 2015;126:684.
   Web of Science ®Google Scholar
• Frey NV, Shaw PA, Hexner EO, et al. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).J. Clin Oncol. 2016;34:7002.
   Google Scholar
• Dunbar CE. Blood’s 70th anniversary: CARs on the blood highway. Blood. 2016;128:1–3.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–1433.
   PubMed Web of Science ®Google Scholar
• Garber HR, Mirza A, Mittendorf EA, et al. Adoptive T-cell therapy for leukemia. Mol Cell Ther. 2014;2:25.
   PubMedGoogle Scholar
• Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165–1174.
   PubMed Web of Science ®Google Scholar
• Torikai H, Reik A, Liu PQ, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012;119:5697–5705.
   PubMed Web of Science ®Google Scholar
• Qasim W, Amrolia PJ, Samarasinghe S, et al. First clinical application of talen engineered universal CAR19 T cells in B-ALL. Blood. 2015;126:2046.
   Web of Science ®Google Scholar
• Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014;257:181–190.
   PubMed Web of Science ®Google Scholar
• Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–4141.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Marcela V. Maus, Carl H. June. Clin Cancer Res. 2016;22:1875–1884.
   PubMed Web of Science ®Google Scholar
• Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965–2973.
   PubMed Web of Science ®Google Scholar
• Gleason MK, Verneris MR, Todhunter DA, et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther. 2012;11:2674–2684.
   PubMed Web of Science ®Google Scholar
• Orentas RJ, Nordlund J, He J, et al. Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison. Front Oncol. 2014;4:134.
   PubMedGoogle Scholar
• Shalabi H, Angiolillo A, Fry TJ. Beyond CD19: opportunities for future development of targeted immunotherapy in pediatric relapsed-refractory acute leukemia. Front Pediatr. 2015;3:80.
   PubMedGoogle Scholar
• Stauss HJ. Engineered T cells can fight malignant T cells. Blood. 2015;126:927–928.
   PubMed Web of Science ®Google Scholar
• Mamonkin M, Rouce RH, Tashiro H, et al. A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983–992.
   PubMed Web of Science ®Google Scholar
• Suryadevara CM, Gedeon PC, Sanchez-Perez L, et al. BiTEs the “missing link” in cancer therapy? Oncoimmunology. 2015;4:e1008339.
   PubMed Web of Science ®Google Scholar